Brain zap test may forecast depression return
NCT ID NCT05579015
First seen Jun 26, 2026 ยท Last updated Jun 26, 2026
Summary
This study tests whether a brain stimulation technique, called theta-burst stimulation, can help predict if depression will come back in people who are currently in remission. Researchers will measure brain activity changes during stimulation using a special imaging cap. The goal is to find a way to identify who is at risk of relapse, so they can get help sooner.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Theta-burst stimulation (TBS) using a device
- What this could lead to
- If successful, this could lead to a way to predict who will have a depression relapse, allowing for earlier intervention.
- What could go wrong
- This is an early-stage observational study, not a treatment trial. The brain stimulation is used only to measure brain activity, not to treat depression. Results may not lead to a reliable prediction method.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Hong Kong Polytechnic University
Hong Kong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test